MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(b)).
“February 4, 2026, Mangoceuticals, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company can regain compliance with the minimum bid price requirement at any time within the 180-calendar day period following receipt of the Nasdaq”
Amanda Hammer changed role as Chief Operating Officer at MANGOCEUTICALS, INC..
“Pursuant to the Hammer Amendment, Ms. Hammer’s role with the Company was expanded to include serving as Chief Operating Officer of Mango & Peaches Corp.,”
Antonios Isaac was appointed as Director at MANGOCEUTICALS, INC..
“appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.”
Antonios Isaac was appointed as President at MANGOCEUTICALS, INC..
“appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.”
Listing & Compliance Notices
MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“filed by the Company with the Commission on November 7, 2023, on November 3, 2023, the Company received a letter from Nasdaq notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the “ Rule ”), which requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the Company reported stockholders’ equity of $1,354,821, which is”
Listing & Compliance Notices
MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“October 30, 2023, the Company received written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues”
Governance Changes
MANGOCEUTICALS, INC.: Filed a Certificate of Designations establishing the 6% Series C Convertible Cumulative Preferred Stock, designating 6,250,000 shares with specific dividend, liquidation, conversion, voting, protective, and redemption terms (effective 2024-04-19).
“On April 19, 2024, the Company submitted for filing to the Secretary of State of Texas, a Certificate of Designations of Mangoceuticals, Inc. Establishing the Designations, Preferences, Limitations and Relative Rights of Its 6% Series C Convertible Cumulative Preferred Stock (the “ Series C Designation ”), which was filed with the Secretary of State of Texas on April 23, 2024, effective as of April 19, 2024.”
M&A Transactions
MANGOCEUTICALS, INC. completed an acquisition involving Intramont Technologies, Inc. for $20,000,000 (closed 2024-04-24).
“infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the “ Patents ”), in consideration for $20,000,000, which is payable to Intramont by (a) the issuance of 980,000 shares of the Company’s newly designated 6% Series C Convertible Preferred Stock (the “ Series C Preferred Stock”
Material Agreements
MANGOCEUTICALS, INC. entered into Patent Purchase Agreement with Intramont Technologies, Inc. valued at $20,000,000 (effective 2024-04-24).
“Mangoceuticals, Inc., a Texas corporation (the “ Company ”, “ we ” and “ us ”), entered into a Patent Purchase Agreement (the “ IP Purchase Agreement ”), with Intramont Technologies, Inc. (“ Intramont ”).”
Material Agreements
MANGOCEUTICALS, INC. entered into Securities Purchase Agreement with an institutional accredited investor valued at $1,650,000 (effective 2024-04-05).
“Effective on April 5, 2024 (the " Initial Closing Date "), Mangoceuticals, Inc., a Texas corporation (the " Company ", " we " and " us "), agreed to definitive terms on a Securities Purchase Agreement dated April 4, 2024 (the " SPA "), with an institutional accredited investor (the " Purchaser "), pursuant to which the Company agreed to sell to the Purchaser, and the Purchaser agreed to purchase from the Company, 1,500 shares of Series B Convertible Preferred Stock (" Series B Preferred Stock ") of the Company for $1,650,000, and warrants”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.